Autolus Therapeutics (AUTL) vs Cabaletta Bio (CABA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Autolus Therapeutics (AUTL) has outperformed Cabaletta Bio (CABA) over the past year, losing 26.2% versus a loss of 55.0%. Over five years, AUTL leads with a -85.5% price change compared with -91.9% for CABA. Autolus Therapeutics is the larger company by market cap ($241.7 million vs $201.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | CABA |
|---|---|---|
| Share price | $0.9073 | $0.9361 |
| Market cap | $241.65M | $201.94M |
| 1-day change | -7.38% | -7.32% |
| YTD return | -54.41% | -57.26% |
| 1-year return | -26.24% | -55.00% |
| 5-year return | -85.51% | -91.93% |
| EPS (TTM) | $-0.96 | $-1.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.39M | — |
| Revenue growth (YoY) | +644.94% | — |
| Net income (latest FY) | $-287.53M | $-167.86M |
| Gross margin | -27.83% | — |
| Operating margin | -358.87% | — |
| Net margin | -381.40% | — |
| 52-week high | $2.58 | $4.23 |
| 52-week low | $0.896 | $0.93 |
| Distance from 52-week high | -64.83% | -77.87% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +821.42% | +1155.21% |
| Average volume | 2.07M | 5.15M |
| Shares outstanding | 266.34M | 215.72M |
| Employees | 752 | 154 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUTL has outperformed CABA by 28.8 percentage points over the past year.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees
AUTL vs CABA FAQ
Which is bigger, Autolus Therapeutics or Cabaletta Bio?
Autolus Therapeutics (AUTL) is larger, with a market capitalization of $241.65M compared with $201.94M for Cabaletta Bio (CABA).
Which stock has performed better over the past year, AUTL or CABA?
AUTL returned -26.24% over the past 12 months, compared with -55.00% for CABA (price return, excluding dividends). Past performance does not predict future results.
Are Autolus Therapeutics and Cabaletta Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.